Bernstein Downgrades Avidity Biosciences to Market Perform, Raises Price Target to $72
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Bernstein analyst William Pickering downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Market Perform and raises the price target from $52 to $72.
Bernstein analyst William Pickering downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Market Perform and raises the price target from $52 to $72.